Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Posted Basic Consolidated EPS Of $-3.9588

0

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) annual basic consolidated EPS was $-3.9588 for the period ended 2015-12-31. The basic consolidated EPS was $-3.9588 for the quarter ended 2015-12-31.

EPS from continuing operations

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s basic EPS from continuing operations was $-3.9588 for the fiscal year 2015-12-31. For the quarter ended 2015-12-31 it stood at $-3.9588

EPS contribution from parent

From the parent company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted basic EPS of $-3.9588 for the fiscal ended 2015-12-31. For the quarter that ended on 2015-12-31 the figure stood at $-3.9588.

Basic net EPS

The Basic net EPS of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was $-3.96 for the period ended 2015-12-31. The figure stood at $-3.96 for the quarter that ended 2015-12-31.

Consolidated diluted EPS

The consolidated diluted EPS for the fiscal year 2015-12-31 stood at $-3.9588. While the figure for the quarter ended 2015-12-31 stood at $-3.9588.

Basic diluted EPS

The diluted EPS from continuing operation of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stood at $-3.9588 for the fiscal 2015-12-31. The figure for the quarter ended 2015-12-31 stood at $-3.9588

Net diluted EPS

The Net diluted EPS was $-3.96 for the fiscal 2015-12-31. The figure for the quarter ended 2015-12-31 stood at $-3.96.

Diluted EPS from parent

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) diluted EPS from the parent company for the fiscal 2015-12-31 was $-3.9588. The figure for the quarter ended 2015-12-31 was $-3.9588

The net basic EPS was $-3.96 for fiscal 2015-12-31. The figure for the quarter ended 2015-12-31 was $-3.96.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 4 times, 1 visits today)